What changed from existing technology?
This study developed and tested different models to check how well a new antibiotic gel works against various bacteria, especially in wounds where multiple bacteria are present.
This study introduces a multi-tiered screening platform that better mimics the wound environment compared to traditional in vitro methods, and evaluates a new 5% ceftriaxone gel as a broad-spectrum alternative to mupirocin.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
es current decolonization strategies. While mupirocin remains the gold standard for MRSA, its inactivity against Pseudomonas aeruginosa creates a critica
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Validation stage
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The developed platform could be used to evaluate new topical antimicrobial agents, particularly for polymicrobial wounds where traditional in vitro methods are insufficient.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.